source
- Sanofi drops Nurix STAT6 degrader program amid molecule-specific concernsSanofi has halted development of an early‑stage STAT6 degrader program that it licensed from Nurix Therapeutics. The decision was announced after the asset entered Phase 1 trials for type 2 inflamm…
- Flagship partner Louisa Helms credits high-school librarian for sparking biotech careerLouisa Helms, a BioSpace 40 Under 40 honoree and partner at Flagship Pioneering, reflects on a unique path into biotech. In high school she was mentored by librarian Tammy Carabello, who turned th…